Skip to main content
main-content

01.12.2011 | Case report | Ausgabe 1/2011 Open Access

Journal of Medical Case Reports 1/2011

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report

Zeitschrift:
Journal of Medical Case Reports > Ausgabe 1/2011
Autoren:
Alexander Shimabukuro-Vornhagen, Achim Rothe, Lucia Nogova, Matthias Kochanek, Christoph Scheid, Michael von Bergwelt-Baildon
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1752-1947-5-215) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ASV wrote the case report. AR contributed to the writing of the case report. LN, MK, and CS analyzed and interpreted the patient data regarding the hematological disease. MvBB analyzed and interpreted the patient data regarding the hematological disease and contributed to the writing and revision of the manuscript. All authors read and approved the final manuscript.

Abstract

Introduction

In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL + clone and often induce complete molecular remissions. Megakaryocytes in such patients have been shown to be derived from the BCR-ABL + clone, and abnormal platelet function is frequent in chronic myeloid leukemia. However, little is known about the influence of modern targeted therapy on chronic myeloid leukemia-associated platelet disorders.

Case presentation

We report the case of a massive hemorrhage in a 32-year-old Caucasian man caused by chronic myeloid leukemia-associated platelet dysfunction, which improved after treatment with imatinib.

Conclusion

This report demonstrates that platelet dysfunction and bleeding disorder in BCR-ABL + chronic myeloid leukemia can successfully be treated with imatinib. We suggest the monitoring of platelet function in future studies using imatinib to treat patients with chronic myeloid leukemia.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2011

Journal of Medical Case Reports 1/2011 Zur Ausgabe